We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck KGAA | TG:MRK | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.45 | 1.65% | 150.65 | 150.00 | 151.30 | 150.95 | 147.95 | 148.15 | 4,455 | 22:50:02 |
From May 2019 to May 2024
The U.S. Federal Trade Commission on Thursday cleared Merck & Co.'s (MRK) $41 billion acquisition of Schering-Plough Corp. (SGP), but required the companies to divest assets as a condition of government approval.
Under the terms of an agreement with the FTC, Merck must sell its interest in Merial Ltd., an animal health joint venture with Sanofi-Aventis SA (SNY, SAN.FR), while Schering-Plough must sell assets in nausea drugs for humans.
The asset sales for nausea drugs were necessary to alleviate competitive concerns regarding human drugs known as NK 1 receptor antagonists, the FTC said.
The drug makers reached their deal in March.
-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com
1 Year Merck KGAA Chart |
1 Month Merck KGAA Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
